Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 9/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4508129 | 0.89 | KDM4E (0.48) | HTTALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4102925 | 0.86 | FES (0.52) | NAMPTALDH1A1SMN1; SMN2 | |
| SCHEMBL4097578 | 0.81 | SMN1; SMN2 (0.52) | ALDH1A1NTRK1SMN1; SMN2 | |
| SCHEMBL4101409 | 0.80 | SLC6A2 (0.61) | HTTSLC6A2SMN1; SMN2 | |
| SCHEMBL4108478 | 0.78 | CA12 (0.52) | HTTSLC6A2ALDH1A1 | |
| SCHEMBL4113322 | 0.74 | BACE1 (0.44) | ALDH1A1GAAMAPT | |
| SCHEMBL21065527 | 0.73 | HTT (0.68) | HTTNAMPTALDH1A1GAAMAPT | |
| SCHEMBL4114519 | 0.72 | CA12 (0.49) | SLC6A2ALDH1A1GAA | |
| SCHEMBL3900501 | 0.71 | MEN1 (0.53) | HTTSLC6A2NAMPTALDH1A1MAPT | |
| SCHEMBL4108710 | 0.70 | RAB9A (0.50) | HTTGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078716-A1 | New derivatives of 1H-indol-1-yl-urea, method for preparing same and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2009-07-15 | — | — | EP | disclosed |
| US-20090176794-A1 | 1H-INDOL-1-YL-UREA COMPOUNDS | LES LABORATOIRES SERVIER (FR) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176794-A1 | 1H-INDOL-1-YL-UREA COMPOUNDS | TPH1, HTR1D, IDO1 | HTT 18/4885SLC6A2 1041/4885NAMPT 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.